Optimism For New Parkinson’s Treatment; Recently Updated RCDI Treatments Are Promising
Read recent pharmaceutical developments in KFF Health News' Prescription Drug Watch roundup.
ScienceDaily:
New Research Provides Hope For Parkinson's Disease Symptom Control
Finding the right medication regimen to treat Parkinson's disease (PD) is a complex healthcare challenge. (Institute for Operations Research and the Management Sciences, 9/12)
CIDRAP:
Breaking The Cycle: New Treatments For Recurrent C Diff (RCDI) Offer An Alternative To Repeated Antibiotics
It's no secret that antibiotics are one of the foundations of modern medicine. Since penicillin was first introduced in the early 1940s, antibiotics have turned once-deadly infections into easily treatable conditions, made surgery and childbirth safer, enabled cancer patients to withstand immune system–sapping chemotherapy, and rendered organ transplants much less risky. But antibiotics don't come without their own risks. Just ask Pamela McCollister. (Dall, 9/11)
CIDRAP:
New Protocols, Education Tied To Less Antibiotic Prescribing For Conjunctivitis
A multifaceted, quality improvement (QI) intervention at a Denver health system was associated with significantly reduced ophthalmic antibiotic prescribing for pediatric conjunctivitis, researchers reported yesterday in the Journal of the Pediatric Infectious Diseases Society. (Dall, 9/12)
Stat:
Neurocrine Congenital Adrenal Hyperplasia Trial Succeeds
Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones. (Wosen, 9/12)
